Parameters | Overall patients | Stage II patients |
---|---|---|
 | n (%) | n (%) |
Sex | ||
 Female | 598 (42.1) | 169 (41.3) |
 Male | 822 (57.9) | 240 (58.7) |
Age (years) | ||
 ≤65 | 669 (47.1) | 198 (48.4) |
 >65 | 751 (52.9) | 211 (51.6) |
Tumor site | ||
 Colon | 846 (59.6) | 217 (53.1) |
 Rectum | 574 (40.4) | 192 (46.9) |
Tumor size (cm) | Â | Â |
 ≤4 | 688 (48.5) | 209 (51.1) |
 >4 | 732 (51.5) | 200 (48.9) |
Lymphovascular invasion | ||
 Positive | 486 (34.2) | 145 (35.5) |
 Negative | 934 (65.8) | 264 (64.5) |
T-stage | Â | Â |
 T1 | 233 (16.4) |  |
 T2 | 393 (27.7) |  |
 T3 | 457 (32.2) | 218 (53.3) |
 T4 | 337 (23.7) | 191 (46.7) |
N-stage | ||
 N0 | 582 (41.0) | 409 (100.0) |
 N1 | 498 (35.1) |  |
 N2 | 340 (23.9) |  |
Differentiation degree | ||
 Well | 666 (46.9) | 198 (48.4) |
 Moderate | 582 (41.0) | 182 (44.5) |
 Poor | 172 (12.1) | 29 (7.1) |
CEA | ||
 ≤5ng/ml | 836 (58.9) | 243 (59.4) |
 >5ng/ml | 584 (41.1) | 166 (40.6) |
CA19-9 | ||
 ≤37U/ml | 1106 (77.9) | 322 (78.7) |
 >37U/ml | 314 (22.1) | 87 (21.3) |
Retrieved LN | Â | Â |
 <12 | 564 (39.7) | 164 (40.1) |
 ≥12 | 856 (60.3) | 245 (59.9) |
Treatment | ||
 ACT | 960 (67.6) | 265 (64.8) |
 SA | 460 (32.4) | 144 (35.2) |
TNM stage | ||
 I | 173 (12.2) |  |
 II | 409 (28.8) |  |
  IIA | 174 (12.3) |  |
  IIB | 121 (8.5) |  |
  IIC | 114 (8.0) |  |
 III | 838 (59.0) |  |
  IIIA | 324 (22.8) |  |
  IIIB | 287 (20.2) |  |
  IIIC | 227 (16.0) |  |
KRAS status | ||
 Wild type | 975 (68.7) | 248 (60.6) |
 Mutant type | 445 (31.3) | 161 (39.4) |
PNI | Â | Â |
 Positive | 276 (19.4) | 90 (22.0) |
 Negative | 1144 (80.6) | 319 (78.0) |
TB | ||
 Low | 995 (70.1) | 294 (71.9) |
 High | 425 (29.9) | 115 (28.1) |